findmyKOL
Clinical trialNCT04606316Active, not recruitingPhase 1Interventional

Surgical Nivolumab And Ipilimumab For Recurrent GBM

SponsorPatrick Wen, MDEnrollment63GBMGlioblastomaGlioblastoma MultiformeGrade IV Astrocytoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma. The names of the study drugs involved in this study are: * Nivolumab * Ipilimumab * Placebo (IV solution with no medicine) * Zr-89 Crefmirlimab berdoxam (optional sub-study)
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of California Los Angeles

    Los Angeles, California, United States

  • Stanford University

    Stanford, California, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ipilimumab →Ipilimumab-PlaceboNivolumab →Nivolumab-Placebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Feb 2021
Primary completion
30 Dec 2026
Completion
31 Dec 2026
Last update posted
17 Feb 2026
Registered enrollment
63
Registry id
NCT04606316
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.